The initial reaction to Telix Pharmaceuticals Ltd (ASX: TLX)'s announcement of a $3.3 billion merger with German company ITM appears lukewarm, with its shares falling more than 6%.
Image source: Getty Images
Building a nuclear medicine powerhouse
The Australian company said in a statement to the ASX that it would pay ITM shareholders an upfront payment of US$1.65 billion, with additional contingent payments of US$700 million.
ITM, Telix said, is the world's leading supplier of therapeutic radioisotopes and the only producer of globally-scaled, commercial-grade lutetium-77.
Telix said regarding the deal:
The merger will further strengthen Telix's leadership as a vertically integrated radiopharmaceutical company with the capabilities required to develop, manufacture and deliver innovative treatments to patients globally. The combined organisation will be uniquely positioned as a radiopharmaceutical industry leader, differentiated by a world-class scaled isotope manufacturing business with a validated global distribution network, a market-leading commercial precision medicine platform and the industry's most extensive therapeutic radiopharmaceutical pipeline.
Telix said ITM grew at a compound annual rate of 40% from 2021 to 2025 and generated US$273 million in revenue in 2025.
Telix added that the global market for radioisotopes was growing, with the nuclear medicine market expected to be worth US$34 billion by 2034.
Telix Managing Director Dr Christian Behrenbruch said:
This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures. ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation. We have enjoyed a close working relationship with ITM for many years and there is strong management alignment for the rationale behind this transaction. By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector.
Telix shares were 6.1% lower on the news at $16.77.
Brokers bullish on Telix Pharmaceuticals shares
Morgan Stanley recently valued the company at $23 per share following the US Food & Drug Administration approving Telix's new drug, Pixclara, an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).
RBC Capital Markets also released a research note at the time, valuing the company at $19.
RBC estimated the total addressable market for Pixclara's current use to be US$140 to US$160 million per year.
The broker added:
Assuming a penetration rate of ~60% in FY35, we estimate Pixclara's first indication would be valued at $0.56/share with further upside potential of $0.62/share if Pixclara achieves ~80% penetration. If the company is successful in securing approval to expand Pixclara's indication to include brain metastases, we estimate this could potentially add as much as ~$3.85/share to our price target.
